数据是制定决策的重要依据之一，做产品推广一定要定期查看数据，通过分析数据，可以了解市场需求和竞争状况，制定更加精准的推广策略和决策，可以 发现推广策略存在的问题和不足之处，从而制定相应的优化措施，提高推广效果和收益。 短链接是企业在营销推广中经常用到的工具，因此最好选择有数据统计功能的短链接生成器，可以有效提升企业推广效率。 短链接访问量统计的核心价值在于，它能让你清楚地看到每一个推广渠道的效果。无论是通过微信群、朋友圈、微信公众号，还是通过电子邮件、网站广 告，甚至是在印刷品或户外广告上，都能精准追踪用户的点击行为，从而评估每个渠道的引流能力。这对于制定更有效的营销策略至关重要。 1. 原始链接与短链接转换 这一步骤非常简单，登录 C1N短链接官网（c1n.cn），在首页把要缩短的长链接复制到文本框内，点击【确定】，就能得到缩短后的链接和二维码，这个链 接将用于后续的访问量统计。 2. 渠道短链接的生成与投放 如果你计划在一个活动中有多个推广渠道，C1N短链接（c1n.cn）还支持一个原始链接生成多个短链接，你可以在后台配置多个不同的名称，这些短链接对 应不同渠道，便于分别跟踪每个渠道的访问量。短链接投放后 ...

Group 1: Company Performance Overview - In the first three quarters of 2025, the company achieved operating revenue of 276 million yuan, a decrease of 5.36% compared to the same period last year [4] - The net profit attributable to shareholders was 67.4 million yuan, down 46.10% year-on-year [4] - The net profit after deducting non-recurring gains and losses reached 59.2 million yuan, a decrease of 45.34% compared to the previous year [4] Group 2: Product Development and Market Strategy - The active biological bone product is a key driver for revenue growth, with ongoing efforts to enhance market coverage and penetration in leading hospitals [5] - The company is actively developing new products, including calcium silicate bio-ceramic bone repair materials, which are in the registration phase [4] - The oral implant market is currently facing weak demand, particularly in the private sector, but the company maintains a stable market position for its oral repair membrane products [5] Group 3: Sales and Marketing Initiatives - The company has established an independent sales team focused on the active biological bone product to enhance market promotion capabilities [7] - Flexible sales policies and long-term relationships with distributors are being pursued to boost product market promotion and hospital admissions [5] - Plans for overseas market expansion are underway, with certain products identified as having export potential [7] Group 4: Research and Development Progress - The company is collaborating with Jiangsu Jicui Future Food Technology Research Institute on the development of recombinant bioactive protein products, with steady progress reported [7] - The research and development of the uterine repair membrane and breast patch products are ongoing, with clinical trials completed for the former [6] Group 5: Investor Relations and Future Outlook - The company has consistently maintained performance dividends since its listing and plans to continue investor return strategies based on overall performance [6] - Employee incentive plans are being developed in accordance with relevant regulations to enhance motivation and performance [6]

Core Insights - The company reported a revenue of 4.659 billion yuan for the first half of 2025, representing a year-on-year increase of 8%, with a net profit attributable to shareholders of 1.203 billion yuan, up 7% year-on-year [1] - The second quarter alone saw a revenue of 2.223 billion yuan, a 7% increase year-on-year, and a net profit of 578 million yuan, which is a significant 25% increase year-on-year [1] Business Segment Performance - The respiratory therapy segment returned to a growth trend with revenues of 1.674 billion yuan, a year-on-year increase of 1.93%, driven by a recovery in oxygen machine sales and over 40% growth in home ventilator products [2] - The blood glucose management and POCT solutions generated revenues of 674 million yuan, reflecting a 20% year-on-year growth, supported by the launch of new CGM products [2] - Home health monitoring solutions achieved revenues of 1.014 billion yuan, up 15.22% year-on-year, with electronic blood pressure monitors showing double-digit growth [2] - Clinical instruments and rehabilitation business reported revenues of 1.134 billion yuan, a 3.32% increase year-on-year, with steady growth in acupuncture needles and wheelchairs [2] - Emergency solutions and other businesses generated revenues of 136 million yuan, marking a 30.54% increase year-on-year [2] Sales and Marketing Strategy - The company increased its sales expenses to 812 million yuan, a rise of 32.99% year-on-year, due to expanded sales scale and increased investments in e-commerce, advertising, and personnel [2] - This short-term pressure on profit growth is expected to positively impact the company's market share expansion both domestically and internationally, driving faster revenue growth in the long term [2] International Market Expansion - The company achieved external sales revenue of 607 million yuan, a year-on-year increase of 26.63%, accounting for 13.03% of total revenue [3] - Products in the emergency field, such as the HeartSave Y|YA series and myPAD series, successfully obtained EU MDR certification [3] - A strategic cooperation agreement with Inogen is expected to accelerate the company's overseas market expansion [3] Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders for 2025-2027 to be 1.989 billion, 2.269 billion, and 2.600 billion yuan, representing year-on-year growth of 10%, 14%, and 15% respectively [4] - The current price corresponds to a PE ratio of 18, 16, and 14 times for the respective years, maintaining a "buy" rating [4]

Financial Data and Key Metrics Changes - The total net revenue for Q2 2025 was $15 million, compared to $14.9 million for Q2 2024, with $2.8 million attributed to the U.S. commercial launch of Amrozi [15][18] - Gross margin increased to 67% in Q2 2025 from 61% in the prior year [15] - Net loss for common shareholders was $3.8 million or $0.16 per share in Q2 2025, compared to a net loss of $3.4 million or $0.17 per share in Q2 2024 [18] Business Line Data and Key Metrics Changes - Amrozi sales contributed approximately $2.8 million to the total net product revenue, marking a significant improvement in gross profit margins [6][15] - Accutane sales declined by $2.3 million due to generic competition, but growth brands like Amrozi and QBREXZA offset this decline [7][15] - QBREXZA revenue for the quarter was reported at $6.9 million [38] Market Data and Key Metrics Changes - Amrozi achieved over 12,800 prescriptions by July, with a consistent increase in weekly prescriptions since its launch [9][11] - The product captured more than 10% of new prescription demand among dermatology writers within three months of promotion [10] - Payer access for Amrozi increased from 30% of commercial lives in May to approximately 65% by July [10] Company Strategy and Development Direction - The company aims to become sustainably EBITDA positive later in 2025 through strategic initiatives focused on optimizing operations and controlling expenses [6] - The focus remains on expanding the base of Amrozi prescribers, growing prescription volume, and increasing payer access [21] - The company is committed to leveraging its established dermatology commercial organization to enhance product sales and profitability [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of Amrozi's launch and its potential to become the standard of care for rosacea treatment [21] - The company is optimistic about achieving its core objectives, which include improving patient lives and creating long-term shareholder value [22] - Management noted that while there is some seasonality in the dermatology market, the current growth trajectory of Amrozi is expected to continue [35] Other Important Information - Journey Medical's common stock was added to the small-cap Russell 2000 and broad market Russell 3000 indexes, enhancing public awareness and institutional investor ownership [13] - The product was featured in a segment on Lifetime TV, increasing visibility [12] Q&A Session Summary Question: What is the goal for coverage by the end of the year? - Management indicated that while they have not publicly disclosed a specific target, they are focused on increasing both the quantity and quality of coverage for Amrozi [24][25] Question: How do you see gross margins evolving over the year? - Management expects incremental improvements in gross margins as Amrozi becomes a larger part of the sales mix, given its low cost [27][28] Question: When will guidance for the year be provided? - Management stated that it is too early in the launch to provide hard guidance and will wait a few more quarters [29] Question: What is the expected net revenue per prescription for Amrozi? - Management refrained from providing specific guidance on average selling price due to the complexities involved in early quarters [33][34] Question: How does seasonality affect the rosacea market? - Management acknowledged some seasonality but believes the current growth pace will not be significantly impacted [35] Question: What is the market share goal for Amrozi? - Management noted that the 10% market share among high-volume dermatologists is a strong start, with expectations for continued growth [48][50]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $20.5 million, down from $23.1 million in the prior year, but above guidance of $18 million to $20 million due to higher shipments to China [6] - Gross margin decreased to 56.4% from 57.2% in Q2 2024, but was at the high end of guidance [6] - Adjusted operating income improved to $1 million from $800,000 in Q2 2024, and adjusted EBITDA increased to $1.5 million from $1.3 million [7][12] - Year-to-date cash flow from operations was strong at $5.7 million compared to $600,000 in the same period last year [13] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 5.4% sequentially and 11.7% year-over-year, primarily due to budget clarity issues for academic institutions [8] - European revenue increased 9% sequentially, driven by stronger academic shipments, while year-over-year revenues were largely flat [10] - APAC revenue decreased over 25% year-over-year due to tariff-related issues, with orders and shipments halting in April but gradually returning to normal [11] Market Data and Key Metrics Changes - The company’s China business accounted for about 10% of revenue, which nearly went to zero in April but has since returned to a more normal run rate [32] - NIH funding delays are extending academic purchasing cycles, but budgets remain in place, with expectations for improvement into 2026 [19] Company Strategy and Development Direction - The company aims to maintain financial discipline, accelerate product adoption, and strengthen its capital structure through refinancing [17][18] - New product pipeline includes the SOHO telemetry platform and the MeSH MEA organoid platform, which are expected to drive future growth [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, believing that the worst of tariff uncertainties is behind them [19] - The company is focused on stabilizing its core business and restructuring its balance sheet to build sustainable sales and profitability [22] Other Important Information - Net debt decreased to $27.9 million from $32 million, reflecting improved operating cash flow and quarterly principal payments [14] - The company has negotiated amendments to its credit facility, providing additional time to refinance and pay down existing debt [15] Q&A Session Summary Question: What do you expect total debt to be by December 5? - The company expects debt to be around $33 million, continuing to pay down $1 million per quarter [26] Question: What are your thoughts on NIH funding and potential budget changes? - Management noted that academic purchasing cycles have been extended, but budgets remain in place, which could benefit the business if conditions improve in 2026 [30] Question: What is your current exposure to China and how did it perform in the quarter? - The China business is about 10% of revenue, which saw a significant decline in April but has returned to normal levels [32]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 declined 4% year over year to $15.9 million, with online sales accounting for 67% of total revenue at $10.6 million [3][4] - Gross profit decreased by 6%, and gross margin fell from 44% in the first quarter of the previous year to 43.1% [4] - Net income for the first quarter was $2 million, down from $2.2 million in the same quarter last year, with basic earnings per share declining from 23¢ to 22¢ [4][5] - Adjusted EBITDA for the quarter was $3.4 million, a 6% decrease compared to the previous year [5] - The company ended the quarter with $12 million outstanding on term loans and no balance on its revolving line of credit, resulting in net debt of $6 million, approximately 0.4 times the company's adjusted EBITDA for the past twelve months [5][13] Business Line Performance Changes - Legacy FitLife revenue for the first quarter was $7.3 million, with wholesale customers contributing 63% and online sales 37%, representing a 5% increase in total revenue [6] - MRC revenue declined 11% year over year to $6.7 million, with gross margin decreasing to 45.4% [7][9] - Muscle Farm revenue declined 6%, with wholesale revenue down 41% and online revenue up 33%, leading to a gross margin drop from 40% to 30.1% [10][11] Market Data and Key Metrics Changes - The tariff environment remains uncertain, particularly concerning ingredients from China, although a recent 90-day de-escalation is seen as encouraging [12] - The company has increased inventory levels intentionally to pre-tariff prices, resulting in an all-time high inventory at the end of the first quarter [12] Company Strategy and Industry Competition - The company aims to be active in M&A, with increased spending on potential transactions, although it cautions that such spending may not always lead to successful acquisitions [13][14] - The company believes it will likely be added to the Russell 2000 index, which could serve as a positive catalyst for the stock [15] Management's Comments on Operating Environment and Future Outlook - Management expressed hope for organic revenue growth in 2025, despite not providing formal guidance [21] - April's performance showed year-over-year increases in total revenue and adjusted EBITDA, although caution was advised regarding the representativeness of these results for the second quarter [17] Other Important Information - The company reported approximately 104,000 active subscribers, accounting for about 30% of online revenue [14] - The company is focusing on new product launches, including bars and ready-to-drink protein beverages, with expectations for increased sales in the second quarter [49][53] Q&A Session Summary Question: Changes in revenue and EBITDA expectations - Management reiterated expectations for organic revenue growth in 2025, without providing specific numbers [20][21] Question: Margins outlook for the year - Management indicated that margins would fluctuate based on product mix and ongoing investments in Muscle Farm [22][24] Question: Performance of Muscle Farm at the wholesale level - Mixed results were reported, with some customers showing increased demand while others did not respond effectively to promotional support [30][33] Question: Update on major customer GNC - Management reported a positive relationship with GNC, with no significant changes since resolving previous issues [40] Question: Status of new product launches - New products are performing well, with expectations for increased sales in the second quarter [49][53] Question: Impact of tariffs on products - Some products benefit from tariff exclusions, while others do not, leading to a variable impact on costs [55][58] Question: Long-term prospects for Muscle Farm - Management expressed disappointment in growth but remains hopeful for future improvements, emphasizing the potential for M&A in the nutritional supplement space [64][75]